Zacks Investment Research upgraded shares of Hill-Rom Holdings Inc. (NYSE:HRC) from a hold rating to a buy rating in a report released on Wednesday. The brokerage currently has $66.00 price target on the medical technology company’s stock.
According to Zacks, “Post a promising third quarter by Hill-Rom, we are upbeat about the company to remain on a solid growth trajectory over the near term. The company’s year-over-year outcome was impressive along with record level of gross margin. Based on several positive catalysts, we expect the company to expand geographically in the coming quarters. Notably, in the last reported quarter, Hill-Rom posted strong growth in both Asia-Pacific and the U.S. While we remain impressed with the company’s increased bottom-line guidance for fiscal 2016, the revenue guidance was quite discouraging. Moreover, Hill-Rom’s persistent poor performance in the International front, especially in the Middle East and Latin America keeps us concerned. Unfortunately no near term improvement can be expected in the existing capital crunch condition that eventually led to economic and political downturns in these economies.”
HRC has been the subject of a number of other research reports. Morgan Stanley raised shares of Hill-Rom Holdings from an equal weight rating to an overweight rating and lifted their price objective for the company from $54.00 to $62.00 in a report on Thursday, June 16th. KeyCorp reissued a buy rating and set a $59.00 target price on shares of Hill-Rom Holdings in a research note on Thursday, June 23rd. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $61.83.
Shares of Hill-Rom Holdings (NYSE:HRC) opened at 60.61 on Wednesday. The company has a 50-day moving average of $58.85 and a 200-day moving average of $52.61. Hill-Rom Holdings has a 52-week low of $42.99 and a 52-week high of $60.98. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 62.42 and a beta of 1.06.
Hill-Rom Holdings (NYSE:HRC) last released its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.05. Hill-Rom Holdings had a net margin of 2.47% and a return on equity of 16.62%. The company earned $655.40 million during the quarter, compared to analysts’ expectations of $647.75 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. Equities research analysts anticipate that Hill-Rom Holdings will post $3.33 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 16th will be given a dividend of $0.17 per share. The ex-dividend date is Wednesday, September 14th. This represents a $0.68 dividend on an annualized basis and a yield of 1.12%. Hill-Rom Holdings’s payout ratio is presently 73.91%.
A number of institutional investors have recently bought and sold shares of HRC. Acrospire Investment Management LLC acquired a new position in Hill-Rom Holdings during the first quarter worth $111,000. BlueMountain Capital Management LLC raised its position in Hill-Rom Holdings by 36.5% in the second quarter. BlueMountain Capital Management LLC now owns 2,343 shares of the medical technology company’s stock worth $118,000 after buying an additional 626 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Hill-Rom Holdings by 30.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,454 shares of the medical technology company’s stock worth $123,000 after buying an additional 568 shares during the last quarter. LS Investment Advisors LLC raised its position in Hill-Rom Holdings by 67.4% in the second quarter. LS Investment Advisors LLC now owns 3,783 shares of the medical technology company’s stock worth $191,000 after buying an additional 1,523 shares during the last quarter. Finally, Bluestein R H & Co. acquired a new position in Hill-Rom Holdings during the second quarter worth $202,000. Hedge funds and other institutional investors own 83.11% of the company’s stock.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.